A Multicenter Phase II Pilot Open Label

NCT ID: NCT01830504

Last Updated: 2016-10-05

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 47 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-04-30
• Study Completion Date: 2017-01-31

Brief Summary

In France, 7-8 000 new thyroid cancer cases are diagnosed each year. Although a good overall prognosis, it is usually estimated that 10 to 20% will rescue and 5% will become metastatic.

The standard treatment of advanced metastatic or recurrent thyroid cancer is limited to radioiodine therapy. It is estimated that 30 to 50% of patients will become resistant to radio iodine. Treatments options are limited in these refractory thyroid patients and long term survival is estimated to less than 10%. Nowadays, no drug is approved in this indication.

The recent explosion in knowledge in tumour biology and the identification of potential biological targets in thyroid cancer led to several clinical trials with targeted therapies, mainly focused on TKI inhibitors targeting the MAPkinase pathway and/or VEGF. Preliminary results were encouraging in papillary thyroid tumors.

Follicular (FTC) and poorly differentiated thyroid (PDTC) cancers account for 10% of thyroid cancer but 20-25% of cancers diagnosed at an advanced stage and near 50% of metastatic refractory thyroid cancers. These cancers with an aggressive behavior represent a major cause of death from thyroid cancer. In these subtypes, targeted therapies gave disappointing results. This may be related to the mutational profile of these tumors which is different from that of papillary cancers. Aberrant activation of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway is thought to play a fundamental role in thyroid tumorigenenesis of follicular and poorly differentiated thyroid cancers. Many genetic alterations have been, recently, identified in this pathway. PIK3CA mutations are found in 10-15% of FTC and can also occur in metastases derived from PDTC. Amplification/genomic copy gain of the PIK3CA has been identified in 24% of FTC and 42% of PDTC. Epigenetic inactivation of PTEN which negatively regulates PI3K has been shown in FTC. Moreover, RAS mutations observed in 20-40% of FTC and PDTC can activate the PI3K/AKT by interacting with the RAS-binding site of the P110 catalytic subunit of PI3K.

Due to the high frequency of activation of PI3K and downstream effectors in progressive, recurrent and poorly differentiated cancers, inhibition of the PI3K signaling pathway with BKM120, a potent pan class I PI3K inhibitor, represents a particularly relevant therapeutic target and should be properly evaluated in advanced follicular and poorly differentiated thyroid carcinomas

Detailed Description

The primary objective of the study will be to determine efficacy of BKM120 as measured by the progression free survival (PFS rate) at 6 months in patients with progressive, metastatic, refractory, follicular or poorly differentiated thyroid cancers.

Conditions

Thyroid Cancers

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

NVP-BKM120 (BKM120) PI3K inhibitor

Group Type: EXPERIMENTAL

BKM120

Intervention Type: DRUG

BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.

A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment.

Interventions

BKM120

BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.

A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Histologically confirmed differentiated follicular or poorly differentiated thyroid cancer

2. Patients refractory to radio iodine: i.e.; absence of radioiodine uptake in at least one target lesion on a post-therapeutic whole body scan, presence of a target lesion after a cumulative radio-iodine activity of at least 600 mCi, patients with radio-iodine uptake who have progression of the disease within 12 months after radioactive iodine (RAI) treatment

3. Metastatic or locally invasive disease

4. Patients must have at least one site of measurable disease per RECIST (version 1.1.)

5. Documented progression as per RECIST (version 1.1.) based on 2 comparative imagings performed within the last 12 months (+20%)

6. Patients may have received two previous treatment with tyrosine kinase inhibitors but must be off treatment within at least 4 weeks

7. Patient has signed the informed consent before any trial related activities and according to local guidelines

8. Patient (male or female) is ≥ 18 years at the day of consenting to the study

9. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 which the investigator believes is stable at the time of screening

10. Patient has adequate bone marrow and organ function as defined by the following laboratory values:

• Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L
• Platelets ≥ 100 x 109/L
• Hemoglobin ≥ 9.0 g/dL
• INR ≤ 1,5
• Potassium, calcium,and magnesium within normal limits (WNL) for theinstitution
• Serum Creatinine ≤ 1.5 x ULN
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range
• Total Serum bilirubin within normal range normal liver function test results, and absence of other contributing disease processes at the time of diagnosis
• Fasting plasma glucose (FPG) ≤ 120 mg/dL or ≤ 6.7 mmol/L
• HbA1c ≤ 8 %

11. Patient has no legal protection measure

12. Patient has a health coverage

Exclusion Criteria

1. Other histological subtypes of thyroid tumors: papillary, anaplastic, medullary, lymphoma or sarcoma

2. Patient has received previous treatment with PI3K and/or mTOR inhibitors or AKT inhibitors,

3. Patient has symptomatic central nervous system (CNS) metastases. Patients with controlled and asymptomatic CNS metastases may participate in this trial. The patient must have completed any prior local treatment for CNS metastases ≥ 28 days (including radiotherapy and/or surgery) prior to enrollment in this study

4. Patient has a concurrent malignancy or malignancy within 3 years of study enrollment,

5. Patient has a score ≥ 12 on the PHQ-9 questionnaire

6. Patient selects a response of "1, 2 or 3" to question number 9 on the PHQ-9 questionnaire regarding potential for suicidal thoughts or ideation

7. Patient has a GAD-7 mood scale score ≥ 15

8. Patient has a medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation

9. Patient is concurrently using other approved or investigational antineoplastic agent

10. Patient who received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered to grade 1 or better from related side effects of such therapy

11. Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects of the surgery

12. Patient has active cardiac disease or a history of cardiac dysfunction including any of the following:Unstable angina pectoris within 6 months prior to study entry,Symptomatic pericarditis,Documented myocardial infarction within 6 months prior to study entry,History of documented congestive heart failure,Documented cardiomyopathy

13. Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)

14. Patient has any of the following cardiac conduction abnormalities:

15. Patient is currently receiving treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes, and the treatment cannot be discontinued or switched to a different medication prior to randomization.

16. Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120

17. Patient is currently receiving increasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agent, as chronic administration of corticosteroids (> 5 days) can induce CYP3A4 The following uses of corticosteroids are permitted: single doses; topical applications, inhaled sprays, eye drops or local injections

18. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment contraindicate patient participation in the clinical study

19. Patient has a history of non-compliance to medical regimen or inability to grant consent

20. Patient is currently receiving treatment with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, The patient must have discontinued strong inducers for at least one week and must have discontinued strong inhibitors before the treatment is initiated. Switching to a different medication prior to entry in the treatment phase is allowed.

21. Patient has a known history of HIV (testing not mandatory) infection

22. Pregnant or nursing (lactating) woman where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive beta hCG laboratory test (> 5 mIU/mL)

23. Patient who does not apply highly effective contraception during the study and through the duration as defined below after the final dose of study treatment.

24. Patient has a known hypersensitivity to any of the excipients of BKM120

25. Patient has not recovered to grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy

26. Patient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hospices Civils de Lyon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Françoise BORSON-CHAZOT, PUPH

Role: STUDY_DIRECTOR

Hospices Civils de Lyon

Locations

Hospices Civils de Lyon

Lyon, , France

Countries

France

References

Borson-Chazot F, Dantony E, Illouz F, Lopez J, Niccoli P, Wassermann J, Do Cao C, Leboulleux S, Klein M, Tabarin A, Eberle MC, Benisvy D, de la Fouchardiere C, Bournaud C, Lasolle H, Delahaye A, Rabilloud M, Lapras V, Decaussin-Petrucci M, Schlumberger M. Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer. Thyroid. 2018 Sep;28(9):1174-1179. doi: 10.1089/thy.2017.0663.

Reference Type: DERIVED

PMID: 30105951 (View on PubMed)

Other Identifiers

2012-748

Identifier Type: -

Identifier Source: org_study_id